A developmentally informed narrative review of Toll-like receptors in adult and pediatric acute respiratory distress syndrome – Foo

Introduction

Acute respiratory misery syndrome (ARDS) in adults, and pediatric ARDS (PARDS) in kids, are extreme, life-threatening types of acute hypoxemic respiratory failure brought on by non-cardiogenic pulmonary edema (1). Mortality charges are excessive, various with sickness severity, geographic location, and air flow technique—starting from 35–52% in adults (2) and 15–40% in kids (3,4). Total, the danger of demise will increase with age (5), although there are some reported mortality peaks at each ends of the age spectrum (6). Amongst survivors, they typically accrue bodily, cognitive, and psychological impairments that contribute considerably to long-term morbidity and healthcare burden (5,7–9).

ARDS and PARDS diagnostic standards differ to deal with age-related elements. The Berlin definition [2012] outlines grownup ARDS analysis, emphasizing PaO₂/FiO₂ ratios, bilateral infiltrates, and ruling out cardiac causes of hypoxemia (10). The Pediatric Acute Lung Damage Consensus Convention (PALICC) offered pediatric-specific standards in 2015 (11). PALICC makes use of radiographic proof of parenchymal lung illness, not requiring bilateral infiltrates, and like the oxygenation index over PaO₂/FiO₂, permitting for various air flow modes and oxygen saturation-based indices given restricted arterial blood fuel availability in kids (11,12). Epidemiological research like LUNG SAFE (2) in adults and PARDIE in pediatrics (3) assist element international ARDS incidence and administration variability. There may be at the moment no focused drug remedy confirmed to constantly decrease mortality in ARDS. Supportive, non-pharmacological therapies reminiscent of low tidal quantity air flow (13), susceptible positioning (14), and conservative fluid methods (15) have decreased mortality. Data gaps stay in PARDS, as most therapies are tailored from grownup research regardless of variations in illness development and immune response by age (5,16).

The central tenet to ARDS pathogenesis entails the breakdown of the alveolar-capillary barrier, leading to elevated vascular permeability, alveolar flooding, hypoxemia, and respiratory failure (Figure 1) (15,17). This disruption is pushed by accidents to each pulmonary endothelium and alveolar epithelium, alongside leukocyte infiltration, platelet aggregation, microvascular thrombosis, and fibrin deposition (18,19). Endothelial dysfunction—together with irritation and disruption of cell junctions—additional will increase vascular leakage and cell demise, fueling lung harm via a self-amplifying immune response (18,20). ARDS typically develops from a variety of direct and oblique triggers reminiscent of sepsis, pneumonia, trauma, or transfusion (2,3), which activate innate immunity by way of sample recognition receptors (PRRs) like Toll-like receptors (TLRs) (21–24). TLRs acknowledge each pathogen-associated molecular patterns (PAMPs), reminiscent of bacterial lipopolysaccharide (LPS), viral RNA, and fungal parts, and damage-associated molecular patterns (DAMPs), together with excessive mobility group field 1 protein (HMGB1), warmth shock proteins (HSPs), mitochondrial DNA, and extracellular ATP (25–34). By sensing each an infection and mobile harm, TLRs play an necessary function in regulating the immune activation within the lungs by bridging exterior insults to inside inflammatory responses. Research on innate immunity have focused upstream inflammatory sensors reminiscent of TLRs, that are important in mediating host responses to each infectious and sterile lung harm (24,35,36). Nevertheless, regardless of rising proof, TLR-directed therapies have but transitioned into scientific observe, indicating the necessity for extra translational analysis on this space (24,36–38). This assessment summarizes the present and rising data on TLR signaling in ARDS, highlighting each infectious and sterile mechanisms of harm, with a particular emphasis positioned on the developmental regulation and translational relevance to PARDS. We intention to focus on limitations in present analysis fashions, developmental distinctions, key mechanistic insights, and data gaps in PARDS. We current this text in accordance with the Narrative Assessment reporting guidelines (accessible at https://atm.amegroups.com/article/view/10.21037/atm-2026-0138/rc).

Determine 1 Pathophysiology of ARDS. In wholesome lungs, the alveolar interface consists of intact epithelial and endothelial limitations, surfactant-producing AEC II, and quiescent AMs. When PAMPs—derived from viral, bacterial or fungal merchandise—enter the alveolar house, they’re acknowledged by TLRs. This recognition triggers downstream inflammatory cascades, together with cytokines reminiscent of IL-1β, IL-6, TNF-α, CCL2, and IFN-β, lots of which recruit neutrophils and monocytes. These cytokines disrupt the alveolar-endothelial barrier by injuring epithelial cells and pulmonary capillary endothelial cells. Barrier disruption will increase vascular permeability, permitting protein-rich fluid and immune cells to enter the alveolar house. Proteinaceous fluid inactivates surfactant, whereas recruited neutrophils launch ROS, selling apoptosis of AEC II cells and additional decreasing surfactant manufacturing. Collectively, these processes exacerbate alveolar collapse and impair fuel trade. Broken AEC II cells and different host cells additionally launch DAMPs, reminiscent of HMGB1 and S100A8/A9, into the alveolar house, the place they’ll re-stimulate TLRs and amplify cytokine and ROS manufacturing. This self-perpetuating inflammatory loop contributes to hallmark options of ARDS pathophysiology, together with diffuse alveolar injury, protein-rich alveolar edema, epithelial cell shedding, and hypoxemia. AEC II, sort II alveolar epithelial cells; AM, alveolar macrophage; ARDS, acute respiratory misery syndrome; DAMP, danger-associated molecular sample; IL, interleukin; PAMP, pathogen-associated molecular sample; ROS, reactive oxygen species; TLR, Toll-like receptor; TNF, tumor necrosis issue.

Strategies

This assessment evaluated the function of TLRs in ARDS and PARDS by looking PubMed/MEDLINE and Google Scholar databases for English-language research as much as Might 2026. Search phrases included “acute respiratory misery syndrome”, “pediatric acute respiratory misery syndrome”, “Toll-like receptor”, “TLR”, “innate immunity”, “lung harm”, “sepsis”, “viral an infection”, “irritation”. and “acute lung harm”, and so forth. The assessment lined experimental, translational, and scientific research on TLR signaling in ARDS/PARDS, prioritizing work on TLR-mediated irritation, improvement of innate immunity, animal fashions, human genetic/transcriptomic information, and therapeutic methods. Examine choice was carried out by a single writer (C.W.T.F.). Foundational analysis on TLR biology and ARDS mechanisms was additionally included. As a result of its narrative method, research choice targeted on relevance fairly than adhering to systematic assessment standards. The search technique abstract seems in Table S1.

Outcomes

Overview of TLRs in ARDS and PARDS

TLRs are germline-encoded receptors which detect conserved microbial motifs termed as PAMPs for innate immune recognition. Every TLR reveals distinct ligand specificity, mobile localization, and downstream signaling structure (18,24,27–32,39–41). Floor-expressed TLRs—reminiscent of TLR1, TLR2, TLR4, TLR5, and TLR6—primarily acknowledge bacterial-derived PAMPs, together with lipoproteins, peptidoglycan, flagellin, and LPS (Figure 2) (29,32,42,43). Amongst these, TLR4, which senses LPS, has been strongly implicated in sepsis-associated ARDS and endotoxin-induced lung harm, with knockout fashions demonstrating profound hypo-responsiveness to LPS (44), leading to attenuated cytokine launch, decreased neutrophilic infiltration, and safety from lung harm. In distinction, endosomal TLRs—TLR3, TLR7, TLR8, and TLR9—acknowledge nucleic acids and mediate viral lung irritation (29,32,42,43,45), together with extreme acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)-induced ARDS (45). Sterile types of ARDS [e.g., trauma, transfusion-related acute lung injury (ALI)] additionally have interaction TLRs by way of DAMPs, for instance, HMGB1 and HSP activate TLR2 and TLR4 (27,29,31), whereas oxidized phospholipids (18) and S100A8/A9 (30) work together with TLR4 (46). A abstract of TLR traits is introduced in Table 1.

Determine 2 Canonical MyD88-dependent and TRIF-dependent pathways of floor and endosomal TLR receptors. In resting cells, floor TLRs exist as monomers. Ligand binding induces homo- or heterodimerization, bringing intracellular Toll/IL-1R (TIR) domains collectively and recruiting TIRAP, MyD88, IRAK1, and IRAK4 to type the Myddosome. IRAK4 phosphorylates IRAK1, enabling TRAF6 interplay, K63-linked auto-ubiquitination, IRAK1 degradation, and IRAK4 recycling. Endosomal TLRs acknowledge viral nucleic acids after viral uptake and endosomal trafficking, endure homodimerization, and activate an identical MyD88-dependent cascade. Ubiquitinated TRAF6 prompts the TAK1-TAB1/2/3 advanced, which drives NF-κB and MAPK signaling. Within the NF-κB pathway, TAK1 prompts IKKβ, resulting in IκBα degradation, NF-κB nuclear translocation, and transcription of inflammatory cytokines together with IL-6, TNF-α, and IL-1β. Within the MAPK pathway, TAK1 prompts MAPKs and downstream JNK, p38, and ERK; JNK and p38 are significantly related to inflammatory signaling in ARDS. TLR4 may also provoke TRIF-dependent signaling after endocytosis, activating NF-κB/MAPK via RIP1, TRAF6, and TAK1, and IRF3-mediated sort I interferon transcription via TRAF3, NAP1, TBK1, and IKKε. TLR3 indicators via TRIF with out TRAM. ARDS, acute respiratory misery syndrome; IL, interleukin; TLR, Toll-like receptor; TNF, tumor necrosis issue.

TLR10 is probably the most not too long ago recognized member of the TLR household and stays one of many least understood, with proof suggesting each anti- and pro-inflammatory capabilities relying on mobile context (32,47,48). In contrast to most TLRs, TLR10 seems to predominantly exert immunomodulatory results, together with suppression of NF-κB, MAPK, and sort I interferon signaling pathways in response to chose bacterial and viral stimuli (47,49). Research have additionally demonstrated a task for TLR10 in regulating responses to viral dsRNA (49), suggesting potential relevance in respiratory viral infections. Nevertheless, the absence of a murine ortholog limits preclinical investigation (47,49–51), and the translational relevance of present TLR10-transgenic mouse fashions stays unsure. To this point, TLR10 has not been immediately studied in both grownup ARDS or PARDS. Given its reported anti-inflammatory properties and involvement in viral innate immune responses, future research ought to consider whether or not TLR10 contributes to the regulation of hyperinflammation in ARDS, significantly in virally mediated PARDS.

Understanding TLR construction, classification, and signaling is important to discern their capabilities in immunity and illness. TLRs are sort I transmembrane proteins with three domains: an extracellular leucine-rich repeat (LRR) area for ligand recognition, a transmembrane area, and a cytoplasmic Toll/interleukin-1 receptor (TIR) area that mediates downstream signaling (52). Synthesized within the endoplasmic reticulum, TLRs are trafficked by chaperone proteins to the cell floor or endosome. They continue to be as monomers till ligand binding triggers dimerization—both as homodimers (e.g., TLR4/TLR4) or as heterodimers (e.g., TLR2/TLR1)—to provoke downstream cascades (52).

TLR signaling pathways

The 2 main TLR downstream signaling pathways are the MyD88-dependent and TRIF-dependent pathways (Figure 2). The MyD88-dependent pathway is utilized by all TLRs excluding TLR3, the place the activation of NF-κB and MAPKs signaling ends in the up-regulation and transcription of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) (21,32,52). However, the TRIF-dependent pathway is simply utilized by TLR3 and partly by TLR4. The TRIF-dependent cascade prompts interferon regulatory elements IRF3 and IRF7, inducing the manufacturing of sort 1 interferons essential for antiviral protection (32,43,52). TLR4 is exclusive as a result of it employs each pathways: MyD88 signaling happens on the plasma membrane, whereas TRIF signaling happens post-endosomal internalization. This spatial segregation of MyD88 and TRIF signaling permits for a coordinated inflammatory and antiviral response (29,43,52). Spatial signaling dynamics affect the result—TRIF-dependent signaling is commonly localized to endosomal compartments, contributing to specificity.

To take care of homeostasis and forestall aberrant TLR signaling, a number of damaging regulatory mechanisms are concerned, together with suppressor regulators (e.g., A20, IRAK-M, SOCS1), ubiquitin-mediated degradation, and decoy receptors (e.g., soluble TLRs) (29,43,52). Latest transcriptomic information from ARDS sufferers present different splicing of key TLR pathway genes, which suggests a context-specific, post-transcriptional fine-tuning of signaling responses (53). Moreover, TLR4 activation has been proven to upregulate TLR3 expression, indicating receptor crosstalk (23,54), and fashions suggest that synergistic TLR/NOD-like receptor (NLR) co-activation could also be the reason for the cytokine storm phenotype in ARDS and coronavirus illness 2019 (COVID-19) (46,55). These signaling pathways coincide with the pathophysiological processes central to ARDS described in grownup sufferers: extreme cytokine launch, leukocyte recruitment, and breakdown of the alveolar-capillary barrier. Although the query of whether or not these mechanisms are noticed uniformly throughout all age teams stays unclear.

Floor TLR activation in experimental ARDS fashions

The TLR4 mannequin is often used to review endotoxin-induced ARDS, as intratracheal or intravenous LPS supply reliably triggers a dose-dependent inflammatory response that mimics key options of human ARDS. These embrace diffuse alveolar injury (56,57), neutrophilic infiltration (18,57,58), together with disruption of alveolar-capillary barrier integrity and the formation of hyaline membrane on account of proteinaceous exudation into the alveolar house (56,57) and elevated pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β) in bronchoalveolar lavage fluid (59). TLR4 signaling initiates cytokine amplification, endothelial leak, and oxidative stress, intently reflecting the exudative section seen in human ARDS.

TLR4-deficient mice demonstrated resistance to LPS, decreased pulmonary irritation, and options resembling ARDS rescue, indicating the significance of TLR4 activation in endotoxin-induced harm (44,60). TLR4 deficiency decreased cytokine launch, neutrophil infiltration, and lung harm (44,60), however in dwell polymicrobial sepsis, full TLR4 deficiency impaired host protection and elevated mortality on account of poor immune response and bacterial unfold (61,62). Endothelial-expressed TLR4 is vital for LPS-induced neutrophil sequestration to the lungs, highlighting the vascular compartment’s function in lung harm (63). TLR4 additionally detects sure viral parts, reminiscent of respiratory syncytial virus (RSV) fusion protein and Ebola virus glycoproteins (64). Since viral infections are a main explanation for PARDS, additional investigations into this TLR’s function in PARDS improvement and development is warranted.

TLR4 activation has been demonstrated in lots of non-infectious fashions of ARDS. In a murine mannequin of ventilator-induced lung harm (VILI), MyD88-dependent TLR4 signaling pathway is demonstrated to induce the discharge of IL-6 and macrophage inflammatory protein 2 (MIP-2), amplifying sterile irritation by way of the TLR4-MyD88 axis (56). In acid aspiration-induced ALI, oxidized phosphatidylcholine—generated via reactive oxygen species-mediated oxidation of membrane polyunsaturated fatty acids—prompts TLR4 independently of MD2 and CD14, requires the TRIF-TRAF6 pathway, and releases IL-6 (18). S100A8/A9 and HMGB1 molecules act as DAMPs exacerbating VILI by way of TLR4, associating intracellular injury to innate immune activation (30,33).

Lastly, TLR4 expression and responsiveness are developmentally regulated (65–67), with neonatal immune cells exhibiting attenuated TLR4 signaling in comparison with adults, influencing susceptibility and inflammatory responses in PARDS. Twine blood mononuclear cells from neonates produce considerably decrease ranges of pro-inflammatory cytokines reminiscent of TNF-α and IL-6 after TLR4 and TLR9 stimulation, with responses step by step rising over the primary 12 months of life. By 12 months, cytokine manufacturing approached 80–90% of grownup ranges, suggesting progressive maturation (65). Equally, monocyte expression of TLR4 in pre-term infants is decreased at start however will increase considerably over the primary three months postnatally, indicating an age-dependent acquisition of innate immune capability (66). Each findings assist the idea that TLR signaling is dynamically programmed throughout youth, modulated by intrinsic developmental cues and environmental exposures (67).

Whereas TLR4 stays probably the most extensively studied receptor in ARDS, the roles of different cell-surface TLRs—TLR1, TLR2, TLR5 and TLR6—have been implicated in pulmonary irritation to a lesser diploma. TLR2 acknowledges bacterial lipoproteins and has been demonstrated in just a few lung harm fashions. In a cecal ligation and puncture (CLP)-induced murine mannequin of sepsis-associated ARDS, TLR2 knockdown attenuated histologic lung harm and suppressed pro-inflammatory cytokine expression, together with TNF-α and IL-6 (19). Equally, TLR2-/- mice subjected to pulmonary contusion exhibited decreased neutrophilic infiltration and alveolar injury, supporting its contributory function in sterile lung harm fashions (68). Proof for TLR5 has been studied in bacterial infection-induced airway irritation fairly than in ARDS, because it didn’t show histopathologic or physiologic ARDS/ALI phenotypes (69). Total, research of TLR1, TLR5 and TLR6 in ARDS stay restricted, suggesting TLR4 to be the dominant floor receptor driving lung harm pathogenesis.

Endosomal TLR activation in experimental ARDS fashions

Endosomal TLRs—TLR3, TLR7, TLR8, and TLR9—mediate responses to viral nucleic acids, triggering irritation. Within the human lung, these receptors are discovered on each non-immune structural cells and immune cells within the airway epithelium and alveolar house, together with alveolar epithelial cells and macrophages (70–72): TLR3 is predominantly expressed in airway epithelial cells (70,71); TLR7/8 are discovered within the plasmacytoid, myeloid dendritic cells (73) and monocytes (74), and TLR9 in B cells and plasmacytoid dendritic cells (75,76). That is in distinction to TLR4, which is ubiquitously expressed throughout each structural and immune cells (77).

In viral an infection fashions like influenza and SARS-CoV-2 (78), endosomal TLRs acknowledge nucleic acids: TLR3 detects dsRNA, TLR7/8 detects ssRNA, and TLR9 senses unmethylated cytosine-phosphate-guanine (CpG) DNA motifs (Table 1). Experimental fashions of endosomal TLR activation have utilized ligands reminiscent of Poly I:C (TLR3 agonist) (42), R848/Imiquimod (TLR7/8 agonists) (79,80), and CpG-oligonucleotides (TLR9 agonist) (29). In contrast to TLR4 fashions, which set off fast cytokine launch and endothelial dysfunction (58), endosomal TLR fashions give attention to epithelial-centric responses with delayed irritation and viral clearance (81). Epithelial TLRs coordinate neutrophil recruitment and cytokine responses, indicating their vital function in viral ARDS (82,83).

TLR3-deficient mice exhibited attenuated cytokine manufacturing, decreased pulmonary irritation, and improved survival following deadly influenza A an infection, regardless of larger viral masses, indicating TLR3-driven irritation primarily causes illness severity (84). In distinction, TLR3/TRIF signaling decreased viral load and illness severity in SARS-CoV-infected mice, suggesting weak TLR3 responses could worsen ARDS by impairing antiviral immunity (78). Non-infectious stimuli like mechanical air flow may also activate TLR3-driven irritation via a MyD88-dependent, TLR4-independent mechanism (85).

TLR7, like TLR3, contributes to viral-induced lung harm. In mice, TLR7 deficiency elevated higher airway irritation however impaired decrease respiratory immunity following influenza A an infection, indicating its compartmentalized immune capabilities (86). TLR7 contributes to each acute and power viral-induced lung harm. Experimental research show that TLR7 activation promotes cytokine launch, barrier dysfunction, and sustained airway irritation (87–89). Latest translational profiling in extreme viral PARDS additional demonstrated interferon-driven immune dysregulation with impaired TLR7-induced IL-1β responses, suggesting that extreme antiviral interferon signaling could paradoxically contribute to dysfunctional innate immunity in pediatric lung harm (74).

Experimental lung harm fashions on TLR8 and TLR9 are restricted. As a result of restricted fashions and lack of useful mouse TLR8 homologs, TLR8’s function in ARDS stays unclear. Transgenic mice expressing TLR8 show lung expression and cytokine response throughout Mycobacterium tuberculosis an infection (90), however their relevance for viral research stays undetermined. TLR9 prompts pulmonary irritation in murine fashions, inflicting neutrophilic infiltration and cytokine launch (91). In a lung contusion mannequin, TLR9-/- mice exhibited decreased cytokines and lung harm, implicating TLR9 activation in sterile trauma-induced lung irritation (92).

Fashions of viral lung harm present some perception into nucleic acid sensing and cytokine manufacturing however don’t seize necessary elements of human ARDS like endothelial harm, multi-phase development, and immune dysregulation (93,94). It’s doable that ARDS animal fashions are restricted by simplified triggers and difficulties replicating human physiology (95).

Multi-TLR activation in experimental ARDS fashions

Particular person TLR activation fashions are restricted in replicating the advanced and assorted nature of scientific ARDS. Animal fashions typically fail to seize elements like immune senescence, co-morbidities, and polymicrobial triggers, resulting in a disconnect between preclinical mechanistic success and scientific outcomes (96–98). The omission of those necessary variables contributes to the translational disconnect between mechanistic success in animal fashions and their failure at bedside, highlighting the complexity of replicating human ARDS in simplified programs (99). Whereas these fashions could present mechanistic insights, they don’t replicate the whole thing of the pathophysiology of ARDS per se (96–98). Sepsis-induced ARDS options broad TLR activation, with elevated TLR2 and TLR4 expression and cytokine manufacturing noticed in septic mice; nevertheless, murine sepsis fashions yield inconsistent ARDS phenotypes and mortality charges (77,100,101).

A CLP mouse mannequin was used to review the activation of a number of TLRs in sepsis-induced ARDS. The discharge of fecal materials into the peritoneal cavity triggers an immune response induced by polymicrobial sepsis, characterised by elevated pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β), neutrophil infiltration and alveolar structural injury (19). Knockdown of TLR2, TLR4, and TLR9 attenuated histopathological lung harm and pro-inflammatory cytokines, specifically TNF-α and IL-6 (19), whereas TLR3 knockdown confirmed no impact, implying that it’s not a pivotal contributor to sepsis-induced lung harm (19). Nevertheless, variability in microbial content material on account of CLP method limits reproducibility and complicates pathogen-TLR interplay evaluation, affecting the interpretation of findings to human instances.

Sterile lung harm fashions present various roles for TLRs in comparison with microbial fashions. The bleomycin-induced lung harm mannequin is also used to research sterile irritation and fibrosis, as intratracheal administration of bleomycin induces epithelial harm, alveolar irritation, and progressive pulmonary fibrosis, which intently resemble human ARDS traits (102). Inhibiting TLR9 on this mannequin reduces lung irritation, cell demise, and fibrosis, suggesting endogenous CpG-rich DNA could drive ARDS by way of the TLR9 pathway (102). Conversely, mice missing each TLR2 and TLR4 undergo worse lung harm and survival after bleomycin publicity on account of impaired restore mechanisms, highlighting the advanced and context-dependent capabilities of a number of TLRs in sterile ARDS (39). Moreover, trauma-hemorrhagic shock fashions point out TLR4 activation by DAMPs or intestine micro organism hyperlinks systemic and lung irritation (103).

Collectively, these research recommend that a number of TLRs contribute to lung harm in ARDS of infective or sterile etiologies, though their roles could fluctuate relying on the context. Consequently, a complete understanding of stimulus-specific and receptor-specific roles in ARDS is essential for the event of focused interventions and fashions.

Massive-animal fashions and translational relevance

Massive-animal ARDS fashions, significantly swine fashions, have been used much less regularly to research particular TLR pathways and are extra generally employed to review the mechanical elements of VILI on account of their shut resemblance to human pulmonary anatomy and physiology. In VILI fashions, the place lung measurement influences mechanical stretch and harm, injurious mechanical air flow submit polytrauma has been proven to induce alveolar injury and irritation (102), doubtlessly involving HMGB1-induced TLR4 activation (33). Different fashions mix acid aspiration or sepsis with injurious mechanical air flow and reproduce key scientific options of ARDS, together with hypoxemia, elevated inflammatory cytokines, and multi-organ dysfunction (103–105). Though direct investigation of TLR signaling in large-animal ARDS fashions stays restricted, these programs present an necessary translational platform for finding out lung harm mechanisms and validating findings generated in small-animal and in vitro fashions.

Human ARDS research: genetic and transcriptomic variation in TLR pathways

Animal research have clarified necessary TLR mechanisms in ARDS, however human ARDS is sophisticated by immune range, co-morbidities, and multi-organ dysfunction. Animal fashions not often seize this complexity, particularly for PARDS, the place juvenile animal fashions are not often used. Age-specific immune responses and lung improvement are sometimes ignored, which problem the adequacy of adult-centric fashions to signify pediatric lung pathophysiology (106). Conversely, age-specific TLR improvement, immune composition, and lung structure stays largely unexamined in preclinical research, limiting their translational software in pediatric illness. To bridge these gaps, human analysis has targeted on blood transcriptomics, immune signaling, and genetics to raised perceive TLR pathways in ARDS. These research can make clear the particular roles of TLRs throughout completely different ages, causes, and scientific outcomes.

Genetic variations in TLR pathways could affect ARDS susceptibility and outcomes. In esophageal most cancers surgical procedure sufferers, TLR4 single-nucleotide polymorphisms (SNPs) elevated the danger and severity of growing postoperative ARDS (107). SNPs within the TLR4/NF-κB signaling axis, TNF-α (rs1800629), IL-6 (rs1800769), and MyD88 (rs7744) had been related to elevated gene expression, better ARDS incidence, and worse prognosis, indicating their potential as prognostic biomarkers (108). Conversely, the TLR4 Asp299Gly (rs4986790) variant was protecting towards extreme COVID-19, highlighting the function of TLR4 genotypes in modulating viral-induced lung harm (109).

Kids with inherited TLR3 deficiency in PARDS developed extreme influenza pneumonitis, linked to TLR3-loss-of-function mutations (e.g., P554S, P680L) (110). These mutations impaired sort I & III interferon responses and viral clearance, highlighting TLR3’s antiviral function within the respiratory epithelium (110). Moreover, TLR3 rs5743313 CT genotype (one C allele, one T allele) is related to extreme pandemic H1N1 influenza instances (111).

Polymorphisms within the promoter of TLR1 (rs5743551, -7202A>G) had been discovered to extend TLR1 floor expression upon LPS publicity, resulting in extreme TNF-α and IL-6 ranges (112). Carriers of this G allele had been extra more likely to develop ALI and had worse outcomes in sepsis-related ARDS, demonstrating that hypermorphic TLR1 signaling could amplify dangerous irritation. This means broader TLR variants past TLR4 justify investigation into ARDS susceptibility and prognosis.

Past DNA-level polymorphisms, post-transcriptional regulation of TLR pathway genes could have an effect on particular person ARDS outcomes. Peripheral blood mononuclear cells (PBMCs) from ARDS sufferers revealed different splicing in key parts like MyD88 and IRAK1 (53). Decrease ranges of the inhibitory MyD88 brief isoform correlated with better illness severity, whereas elevated expression of an IRAK1 variant missing exon 11 was noticed (53). These splice variants doubtless affect irritation and will clarify variability in ARDS severity and remedy responses.

Pediatric views: developmental regulation of TLR signaling

Infants and younger kids present age-dependent variations in TLR expression and performance that will affect susceptibility, illness severity, and therapeutic responses in PARDS. In contrast with adults, neonates and infants show attenuated TLR-mediated cytokine exercise and a relative Th2-skewed immune profile, suggesting developmental modulation of innate immune responses (66,80,113,114). Moreover, TLR2 regulation seems to be developmentally variable whereas TLR4-mediated endotoxin sensing stays comparatively conserved throughout youth, indicating receptor-specific maturation patterns (115). Regardless of rising recognition that TLR signaling is developmentally regulated (116–118), few research have immediately examined how these age-related variations affect PARDS pathobiology. Understanding these developmental trajectories is important for decoding pediatric lung harm and for designing age-appropriate immunomodulatory therapies.

In youth, TLR signaling is tightly regulated, with neonates and kids displaying distinct receptor profiles and cytokine responses in comparison with adults. Analysis signifies that innate immune responses, particularly these mediated by TLRs, mature at completely different charges: for instance, TNF-α and IL-6 responses method grownup ranges by 12 months (65,67), whereas TLR3-driven IFN-β manufacturing continues rising via 24 months (67,119). These findings present that innate immunity develops alongside distinctive timelines for every TLR, suggesting infants and toddlers could have completely different lung-inflammatory profiles and thus various dangers and remedy responses in PARDS.

On the mobile degree, pre-term and time period neonates exhibit attenuated TLR-mediated responses, together with decreased IL-6 and TNF-α manufacturing following TLR4 (LPS) and TLR9 (CpG) stimulation, which can contribute to impaired early-life an infection management (120). Developmental variations prolong past receptor expression, with age-related adjustments in transcriptional regulation influencing cytokine responses following TLR activation (121,122). Neonatal immune cells additionally preferentially undertake regulatory and Th2-skewed cytokine applications, together with elevated IL-10 manufacturing, doubtlessly limiting extreme irritation on the expense of environment friendly pathogen clearance (118). Per these findings, longitudinal research have demonstrated age-dependent will increase in TLR-induced cytokine responses all through infancy and early childhood, confirming that TLR operate continues to mature past the neonatal interval (116,123). Collectively, these observations assist the idea that pediatric innate immune responses are qualitatively distinct from adults, in step with pulmonary immune profiling research in extreme viral PARDS demonstrating interferon-dominant immune signatures and altered TLR7-associated cytokine responses (74).

Latest experimental work extends this idea: co-stimulation of TLR7/8 and the C-type lectin Mincle in new child dendritic cells uniquely enabled Th-1 polarization—a pathway underrepresented in youth (124). Moreover, transcriptomic signatures in pediatric septic shock sufferers differ with rising age, implying that innate applications hold evolving properly into childhood (125). Basic disparities in lung harm responses between childhood and adults are famous too (126,127), emphasizing the significance of integrating age-specific variations in immunologic responses in PARDS fashions. Subsequently, these research paint a unified image: TLR pathways should not merely “dampened” in kids however mature in a ligand- and receptor-specific method, implying that the severity of pediatric lung harm will fluctuate with each age and nature of the PAMP or DAMP stimulus.

Whereas these developmental research should not PARDS particular, they supply necessary organic context for age-stratified pediatric lung harm. In a sepsis-related ARDS mannequin, administration of IFN-β restored alveolar macrophage operate, decreased TNF-α and IL-6 ranges, improved bacterial clearance, and enhanced survival (128). Though direct research in ARDS stay restricted, IFN-β has additionally been proposed—primarily based on its recognized epithelial-protective properties—to strengthen alveolar barrier integrity and promote surfactant launch, suggesting further mechanisms by which TRIF/TLR3-driven IFN-β may ameliorate lung harm. On condition that TLR3-mediated IFN-β responses proceed to mature all through early childhood (119), developmental variations on this pathway could contribute to age-dependent variation in host responses to lung harm and an infection. Against this, TLR2/4 signaling reaches near-adult ranges by roughly 12 months of age (119), suggesting that receptor-specific maturation could affect how PARDS manifests throughout completely different pediatric age teams. These developmental variations could partly contribute to the distinct scientific phenotypes and final result patterns noticed between pediatric and grownup ARDS, though direct proof stays restricted.

Regardless of rising proof that TLR signaling is developmentally regulated, direct investigation of TLR pathways in PARDS stays extraordinarily restricted. To this point, solely a small variety of research have recognized polymorphisms in TLR2 (rs5743708) and TLR4 (rs4986790) related to susceptibility to infectious ARDS in kids (129). Most pediatric research have as an alternative targeted on downstream inflammatory mediators, with elevated ranges of IL-6, IL-8, MCP-1, IP-10, TNF-α, IL-12p70, IL-17A, GM-CSF, and IFN-α in extreme PARDS sufferers (130). A number of of those cytokines are canonical downstream merchandise of TLR signaling pathways, suggesting that innate immune activation contributes to illness pathogenesis. Latest multi-omics pulmonary immune profiling additional demonstrated interferon-driven immune dysregulation and suppression of TLR7-induced IL-1β responses in extreme viral PARDS, highlighting pediatric-specific innate immune mechanisms distinct from these described in grownup (74). Collectively, these findings recommend that whereas downstream signatures of TLR activation are detectable in PARDS, the upstream receptor-level mechanisms stay largely unexplored. Consequently, future research ought to combine age-stratified analyses with direct evaluation of TLR expression, signaling, and performance to raised outline the contribution of innate immune pathways to PARDS pathobiology.

Rising TLR-targeted therapies in ARDS

Given the central function of TLR signaling in ARDS pathogenesis, a number of TLR-targeted therapies have been evaluated in preclinical fashions and early-phase scientific research. Nevertheless, their restricted success in scientific trials illustrates a recurrent translational drawback: inhibition of a single innate immune receptor not often matches the organic complexity of ARDS. Eritoran, a TLR4 antagonist, improved survival in influenza-infected mice (131,132), however didn’t cut back mortality in sufferers with extreme sepsis (133). This failure doubtless displays a number of elements: trial populations weren’t enriched for sufferers with demonstrable TLR4- or endotoxin-driven biology; remedy could have been administered after downstream inflammatory cascades had been already established; and sepsis-associated ARDS entails redundant PAMP- and DAMP-sensing pathways, together with TLR2, TLR9, complement, inflammasomes, and endothelial harm pathways. Thus, blockade of TLR4 alone could also be biologically inadequate as soon as systemic irritation, immunosuppression, coagulopathy, and multi-organ dysfunction have advanced. Direct viral lung harm might also differ essentially from oblique extrapulmonary ARDS, as pulmonary-compartmentalized antiviral irritation could have interaction distinct TLR-adaptor applications in contrast with polymicrobial sepsis.

Different brokers not directly modulating TLR4 have proven profit in preclinical research. Propofol, a standard anesthetic agent, was proven to suppress the TLR4-HMGB1 axis (134), attenuating cytokine launch and lung harm in experimental fashions. TAK-242, a selective inhibitor of intracellular TLR4-TIR area signaling (135), potently suppressed TLR4-mediated signaling in murine and human cell fashions, but did not considerably cut back IL-6 ranges or enhance scientific outcomes in a randomized placebo-controlled extreme sepsis trial (136). These outcomes recommend that focus on engagement in simplified experimental programs doesn’t assure significant pharmacodynamic suppression in critically in poor health sufferers. Scientific ARDS encompasses variable timing of harm onset, combined infectious and sterile triggers, variations in hyperinflammatory versus hypoinflammatory phenotypes, variable pathogen burden, and concurrent supportive therapies. With out biomarker-guided enrichment, a remedy that will profit a slim TLR-driven subgroup can seem ineffective when examined throughout an unselected syndrome-level inhabitants.

Endosomal TLR antagonists additional spotlight the issue of balancing immune suppression towards host protection. Chloroquine (102), hydroxychloroquine (137), and ODN2088 (TLR7/9 inhibitor) (102,138) decreased irritation in murine fashions by impairing ligand binding or endosomal acidification. Nevertheless, the route of impact is extremely timing-dependent: early TLR7 antagonism can impair viral clearance, whereas later inhibition could cut back immune-mediated harm (88). This duality could clarify why broadly dampening antiviral innate sensing has not constantly improved scientific outcomes. IL-1 blockade utilizing anakinra in a murine COVID-19 ARDS mannequin displayed efficacy in decreasing classical hallmarks of irritation (139), however didn’t shorten time to scientific enchancment in adults (140). IL-6 blockade with tocilizumab confirmed encouraging observational indicators (141), however bigger randomized trials, together with COV-AID (140), did not show constant survival advantages or enhancements in main scientific endpoints. In distinction, the JAK1/2 inhibitor baricitinib demonstrated a discount in mortality within the section III COV-BARRIER trial (142,143) regardless of not assembly all main endpoints, supporting the likelihood that broader modulation of convergent downstream inflammatory pathways could also be simpler than receptor- or cytokine-specific blockade in heterogeneous ARDS populations.

Newer methods embrace prophylactic TLR activation to prime antiviral immunity. Moderately than suppressing irritation, this method seeks to induce a transient antiviral state previous to an infection by enhancing innate immune readiness and selling early interferon-mediated responses (144). Intranasal TLR2 agonism is being investigated as a preventative remedy able to offering broad safety towards respiratory viruses (144), an method which may be significantly related to viral PARDS, the place respiratory viral infections reminiscent of rhinovirus are necessary etiologic contributors (145). However, this technique could also be dangerous in pediatric populations, significantly in tropical areas the place respiratory virus circulation is much less predictable, as a result of pointless TLR activation may provoke irritation in uninfected people or in kids with developmentally distinct immune responses. A abstract of potential TLR-associated therapies for ARDS is introduced in Table 2.

Translational challenges

The translational problem for TLR-targeted remedy in ARDS lies not within the absence of organic rationale, however within the problem of matching a particular immune pathway to the suitable affected person, illness stage, and scientific endpoint. The failure of TLR-directed brokers in scientific trials ought to due to this fact not be interpreted as proof that TLRs are irrelevant to ARDS pathobiology. Moderately, it highlights a number of recurring limitations: ARDS is a syndrome with heterogeneous infectious and sterile triggers, TLR activation could also be protecting early however pathogenic later, and downstream inflammatory cascades could already be established by the point remedy is initiated. As well as, single-receptor blockade could also be inadequate in a illness state characterised by redundant PAMP- and DAMP-sensing pathways, receptor crosstalk, endothelial harm, immunosuppression, and multi-organ dysfunction. These points are particularly related to PARDS, the place developmental variations in TLR expression and cytokine responses could alter each therapeutic efficacy and threat.

A number of proof gaps additional restrict translation. First, this assessment focuses particularly on TLR signaling and due to this fact doesn’t comprehensively deal with the broader community of innate immune receptors concerned in ARDS and PARDS. Different PRRs, together with NLRs, RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs), additionally contribute to pathogen sensing, sterile irritation, and immune regulation, typically via intensive crosstalk with TLR pathways. Consequently, a TLR-centered framework gives solely a partial view of the innate immune panorama underlying lung harm. Second, a lot of the mechanistic proof is derived from in vitro programs and animal fashions that won’t absolutely recapitulate the heterogeneity, temporal evolution, compartment-specific biology, and scientific complexity of human ARDS. Third, direct research of TLR signaling in PARDS stay scarce, requiring substantial reliance on grownup ARDS information and developmental immunology research to deduce pediatric mechanisms. Future translational research ought to due to this fact incorporate PAMP- and DAMP-associated biomarkers, inflammatory subphenotyping, longitudinal and compartment-specific immune profiling, multi-omics approaches, and age-stratified enrollment throughout grownup and pediatric cohorts. Such designs might be important to find out whether or not TLR signaling is protecting, pathogenic, or already bypassed on the time of intervention, and to outline when TLR modulation is more than likely to be protected and biologically efficient.

Conclusions

TLRs play a mechanistic function in pathogenesis of ARDS, particularly TLR4 in sepsis-induced lung harm and TLR3/TLR7 in viral lung harm. Nevertheless, understanding of TLR involvement in PARDS stays restricted and is basically extrapolated from grownup and animal research that don’t adequately account for age-specific variations in TLR expression and signaling. These developmental variations could contribute to distinct immune responses and scientific phenotypes between ARDS and PARDS, emphasizing the necessity for pediatric-focused analysis. Future research ought to prioritize age-stratified scientific and translational investigations that account for developmental stage, illness etiology, immune phenotype, and remedy timing to raised outline the function of TLR signaling in PARDS.

Acknowledgments

None.

Reporting Guidelines: The authors have accomplished the Narrative Assessment reporting guidelines. Obtainable at https://atm.amegroups.com/article/view/10.21037/atm-2026-0138/rc

Peer Assessment File: Obtainable at https://atm.amegroups.com/article/view/10.21037/atm-2026-0138/prf

Funding: None.

Conflicts of Curiosity: All authors have accomplished the ICMJE uniform disclosure type (accessible at https://atm.amegroups.com/article/view/10.21037/atm-2026-0138/coif). J.J.M.W. serves as an unpaid editorial board member of Annals of Translational Medication from February 2026 to December 2027. The opposite authors haven’t any conflicts of curiosity to declare.

Moral Assertion: The authors are accountable for all elements of the work in guaranteeing that questions associated to the accuracy or integrity of any a part of the work are appropriately investigated and resolved.

Open Entry Assertion: That is an Open Entry article distributed in accordance with the Artistic Commons Attribution-NonCommercial-NoDerivs 4.0 Worldwide License (CC BY-NC-ND 4.0), which allows the non-commercial replication and distribution of the article with the strict proviso that no adjustments or edits are made and the unique work is correctly cited (together with hyperlinks to each the formal publication via the related DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Ashbaugh DG, Bigelow DB, Petty TL, et al. Acute respiratory misery in adults. Lancet 1967;2:319-23. [Crossref] [PubMed]
2. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Sufferers With Acute Respiratory Misery Syndrome in Intensive Care Models in 50 International locations. JAMA 2016;315:788-800. [Crossref] [PubMed]
3. Khemani RG, Smith L, Lopez-Fernandez YM, et al. Paediatric acute respiratory misery syndrome incidence and epidemiology (PARDIE): a world, observational research. Lancet Respir Med 2019;7:115-28. [Crossref] [PubMed]
4. Wong JJ, Jit M, Sultana R, et al. Mortality in Pediatric Acute Respiratory Misery Syndrome: A Systematic Assessment and Meta-Evaluation. J Intensive Care Med 2019;34:563-71. [Crossref] [PubMed]
5. Patel BM, Reilly JP, Bhalla AK, et al. Affiliation between Age and Mortality in Pediatric and Grownup Acute Respiratory Misery Syndrome. Am J Respir Crit Care Med 2024;209:871-8. [Crossref] [PubMed]
6. Killien EY, Mills B, Vavilala MS, et al. Affiliation between age and acute respiratory misery syndrome improvement and mortality following trauma. J Trauma Acute Care Surg 2019;86:844-52. [Crossref] [PubMed]
7. Biehl M, Kashyap R, Ahmed AH, et al. Six-month quality-of-life and useful standing of acute respiratory misery syndrome survivors in comparison with sufferers in danger: a population-based research. Crit Care 2015;19:356. [Crossref] [PubMed]
8. Bienvenu OJ, Colantuoni E, Mendez-Tellez PA, et al. Cooccurrence of and remission from basic nervousness, melancholy, and posttraumatic stress dysfunction signs after acute lung harm: a 2-year longitudinal research. Crit Care Med 2015;43:642-53. [Crossref] [PubMed]
9. Loh SW, Gan MY, Wong JJ, et al. Excessive burden of acquired morbidity in survivors of pediatric acute respiratory misery syndrome. Pediatr Pulmonol 2021;56:2769-75. [Crossref] [PubMed]
10. ARDS Definition Activity Power. Acute respiratory misery syndrome: the Berlin Definition. JAMA 2012;307:2526-33. [Crossref] [PubMed]
11. Pediatric acute respiratory misery syndrome: consensus suggestions from the Pediatric Acute Lung Damage Consensus Convention. Pediatr Crit Care Med 2015;16:428-39.
12. Emeriaud G, López-Fernández YM, Iyer NP, et al. Government Abstract of the Second Worldwide Pointers for the Prognosis and Administration of Pediatric Acute Respiratory Misery Syndrome (PALICC-2). Pediatr Crit Care Med 2023;24:143-68. [Crossref] [PubMed]
13. Acute Respiratory Misery Syndrome Community. Air flow with decrease tidal volumes as in contrast with conventional tidal volumes for acute lung harm and the acute respiratory misery syndrome. N Engl J Med 2000;342:1301-8. [Crossref] [PubMed]
14. Guérin C, Reignier J, Richard JC, et al. Susceptible positioning in extreme acute respiratory misery syndrome. N Engl J Med 2013;368:2159-68. [Crossref] [PubMed]
15. Nationwide Coronary heart, Lung, and Blood Institute Acute Respiratory Misery Syndrome (ARDS) Scientific Trials Community, Wiedemann HP, Wheeler AP, et al. Comparability of two fluid-management methods in acute lung harm. N Engl J Med 2006;354:2564-75.
16. Kneyber MCJ, Khemani RG, Bhalla A, et al. Understanding scientific and organic heterogeneity to advance precision drugs in paediatric acute respiratory misery syndrome. Lancet Respir Med 2023;11:197-212. [Crossref] [PubMed]
17. Bos LDJ, Ware LB. Acute respiratory misery syndrome: causes, pathophysiology, and phenotypes. Lancet 2022;400:1145-56. [Crossref] [PubMed]
18. Imai Y, Kuba Okay, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung harm. Cell 2008;133:235-49. [Crossref] [PubMed]
19. Chen X, Wang T, Tune L, et al. Activation of a number of Toll-like receptors serves completely different roles in sepsis-induced acute lung harm. Exp Ther Med 2019;18:443-50. [Crossref] [PubMed]
20. Grunwell JR, Stephenson ST, Dallalio GA, et al. Growth of an acute lung harm mannequin for drug testing. Sci Rep 2025;15:17703. [Crossref] [PubMed]
21. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216. [Crossref] [PubMed]
22. Gayed PM. Towards a contemporary synthesis of immunity: Charles A. Janeway Jr. and the immunologist’s soiled little secret. Yale J Biol Med 2011;84:131-8.
23. Ding X, Jin S, Tong Y, et al. TLR4 signaling induces TLR3 up-regulation in alveolar macrophages throughout acute lung harm. Sci Rep 2017;7:34278. [Crossref] [PubMed]
24. Kawai T, Ikegawa M, Ori D, et al. Decoding Toll-like receptors: Latest insights and views in innate immunity. Immunity 2024;57:649-73. [Crossref] [PubMed]
25. Ware LB, Matthay MA. The acute respiratory misery syndrome. N Engl J Med 2000;342:1334-49. [Crossref] [PubMed]
26. Riteau N, Gasse P, Fauconnier L, et al. Extracellular ATP is a hazard sign activating P2X7 receptor in lung irritation and fibrosis. Am J Respir Crit Care Med 2010;182:774-83. [Crossref] [PubMed]
27. Yang H, Hreggvidsdottir HS, Palmblad Okay, et al. A vital cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine launch. Proc Natl Acad Sci U S A 2010;107:11942-7. [Crossref] [PubMed]
28. Zhang Q, Itagaki Okay, Hauser CJ. Mitochondrial DNA is launched by shock and prompts neutrophils by way of p38 map kinase. Shock 2010;34:55-9. [Crossref] [PubMed]
29. Kawai T, Akira S. Toll-like receptors and their crosstalk with different innate receptors in an infection and immunity. Immunity 2011;34:637-50. [Crossref] [PubMed]
30. Kuipers MT, Vogl T, Aslami H, et al. Excessive ranges of S100A8/A9 proteins irritate ventilator-induced lung harm by way of TLR4 signaling. PLoS One 2013;8:e68694. [Crossref] [PubMed]
31. Tian J, Guo X, Liu XM, et al. Extracellular HSP60 induces irritation via activating and up-regulating TLRs in cardiomyocytes. Cardiovasc Res 2013;98:391-401. [Crossref] [PubMed]
32. Fore F, Indriputri C, Mamutse J, et al. TLR10 and Its Distinctive Anti-Inflammatory Properties and Potential Use as a Goal in Therapeutics. Immune Netw 2020;20:e21. [Crossref] [PubMed]
33. Younger MD, Cancio TS, Thorpe CR, et al. Circulatory HMGB1 is an early predictive and prognostic biomarker of ARDS and mortality in a swine mannequin of polytrauma. Entrance Immunol 2023;14:1227751. [Crossref] [PubMed]
34. Su Y, Lucas R, Fulton DJR, et al. Mechanisms of pulmonary endothelial barrier dysfunction in acute lung harm and acute respiratory misery syndrome. Chin Med J Pulm Crit Care Med 2024;2:80-7. [Crossref] [PubMed]
35. Burnham EL, Janssen WJ, Riches DW, et al. The fibroproliferative response in acute respiratory misery syndrome: mechanisms and scientific significance. Eur Respir J 2014;43:276-85. [Crossref] [PubMed]
36. Arora S, Ahmad S, Irshad R, et al. TLRs in pulmonary illnesses. Life Sci 2019;233:116671. [Crossref] [PubMed]
37. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-83. [Crossref] [PubMed]
38. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein indicators activation of adaptive immunity. Nature 1997;388:394-7. [Crossref] [PubMed]
39. Jiang D, Liang J, Fan J, et al. Regulation of lung harm and restore by Toll-like receptors and hyaluronan. Nat Med 2005;11:1173-9. [Crossref] [PubMed]
40. Schaefer L, Babelova A, Kiss E, et al. The matrix part biglycan is proinflammatory and indicators via Toll-like receptors 4 and a pair of in macrophages. J Clin Make investments 2005;115:2223-33. [Crossref] [PubMed]
41. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs trigger inflammatory responses to harm. Nature 2010;464:104-7. [Crossref] [PubMed]
42. Akira S, Takeda Okay. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511. [Crossref] [PubMed]
43. O’Neill LA, Golenbock D, Bowie AG. The historical past of Toll-like receptors – redefining innate immunity. Nat Rev Immunol 2013;13:453-60. [Crossref] [PubMed]
44. Poltorak A, He X, Smirnova I, et al. Faulty LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-8. [Crossref] [PubMed]
45. Poulas Okay, Farsalinos Okay, Zanidis C. Activation of TLR7 and Innate Immunity as an Environment friendly Methodology In opposition to COVID-19 Pandemic: Imiquimod as a Potential Remedy. Entrance Immunol 2020;11:1373. [Crossref] [PubMed]
46. Le J, Kulatheepan Y, Jeyaseelan S. Position of toll-like receptors and nod-like receptors in acute lung an infection. Entrance Immunol 2023;14:1249098. [Crossref] [PubMed]
47. Jiang S, Li X, Hess NJ, et al. TLR10 Is a Detrimental Regulator of Each MyD88-Dependent and -Unbiased TLR Signaling. J Immunol 2016;196:3834-41. [Crossref] [PubMed]
48. Mourits VP, Arts RJW, Novakovic B, et al. The function of Toll-like receptor 10 in modulation of skilled immunity. Immunology 2020;159:289-97. [Crossref] [PubMed]
49. Lee SM, Yip TF, Yan S, et al. Recognition of Double-Stranded RNA and Regulation of Interferon Pathway by Toll-Like Receptor 10. Entrance Immunol 2018;9:516. [Crossref] [PubMed]
50. Oosting M, Cheng SC, Bolscher JM, et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci U S A 2014;111:E4478-84. [Crossref] [PubMed]
51. Knez Š, Narat M, Ogorevc J. TLR10 overexpression modulates immune response in A549 lung epithelial cells challenged with SARS-CoV-2 S and N proteins. Entrance Immunol 2024;15:1490478. [Crossref] [PubMed]
52. Li D, Wu M. Sample recognition receptors in well being and illnesses. Sign Transduct Goal Ther 2021;6:291. [Crossref] [PubMed]
53. Blumhagen RZ, Hedin BR, Malcolm KC, et al. Various pre-mRNA splicing of Toll-like receptor signaling parts in peripheral blood mononuclear cells from sufferers with ARDS. Am J Physiol Lung Cell Mol Physiol 2017;313:L930-9. [Crossref] [PubMed]
54. Newton Okay, Dixit VM. Signaling in innate immunity and irritation. Chilly Spring Harb Perspect Biol 2012;4:a006049. [Crossref] [PubMed]
55. Root-Bernstein R. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Assessment and Mannequin Making Novel Predictions and Therapeutic Strategies. Int J Mol Sci 2021;22:2108. [Crossref] [PubMed]
56. Li H, Su X, Yan X, et al. Toll-like receptor 4-myeloid differentiation issue 88 signaling contributes to ventilator-induced lung harm in mice. Anesthesiology 2010;113:619-29. [Crossref] [PubMed]
57. Tsikis ST, Fligor SC, Hirsch TI, et al. Lipopolysaccharide-induced murine lung harm ends in long-term pulmonary adjustments and downregulation of angiogenic pathways. Sci Rep 2022;12:10245. [Crossref] [PubMed]
58. Hu G, Malik AB, Minshall RD. Toll-like receptor 4 mediates neutrophil sequestration and lung harm induced by endotoxin and hyperinflation. Crit Care Med 2010;38:194-201. [Crossref] [PubMed]
59. Dhlamini Q, Wang W, Feng G, et al. FGF1 alleviates LPS-induced acute lung harm by way of suppression of irritation and oxidative stress. Mol Med 2022;28:73. [Crossref] [PubMed]
60. Hoshino Okay, Takeuchi O, Kawai T, et al. Leading edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: proof for TLR4 because the Lps gene product. J Immunol 1999;162:3749-52.
61. Zhang M, Zou L, Feng Y, et al. Toll-like receptor 4 is important to preserving cardiac operate and survival in low-grade polymicrobial sepsis. Anesthesiology 2014;121:1270-80. [Crossref] [PubMed]
62. Zhou D, Zhu Y, Ouyang MZ, et al. Knockout of Toll-like receptor 4 improves survival and cardiac operate in a murine mannequin of extreme sepsis. Mol Med Rep 2018;17:5368-75. [Crossref] [PubMed]
63. Andonegui G, Bonder CS, Inexperienced F, et al. Endothelium-derived Toll-like receptor-4 is the important thing molecule in LPS-induced neutrophil sequestration into lungs. J Clin Make investments 2003;111:1011-20. [Crossref] [PubMed]
64. Olejnik J, Hume AJ, Mühlberger E. Toll-like receptor 4 in acute viral an infection: An excessive amount of of a very good factor. PLoS Pathog 2018;14:e1007390. [Crossref] [PubMed]
65. Nguyen M, Leuridan E, Zhang T, et al. Acquisition of adult-like TLR4 and TLR9 responses through the first 12 months of life. PLoS One 2010;5:e10407. [Crossref] [PubMed]
66. Shen CM, Lin SC, Niu DM, et al. Growth of monocyte Toll-like receptor 2 and Toll-like receptor 4 in preterm newborns through the first few months of life. Pediatr Res 2013;73:685-91. [Crossref] [PubMed]
67. Anthoney N, Foldi I, Hidalgo A. Toll and Toll-like receptor signalling in improvement. Growth 2018;145:dev156018. [Crossref] [PubMed]
68. Hoth JJ, Hudson WP, Brownlee NA, et al. Toll-like receptor 2 participates within the response to lung harm in a murine mannequin of pulmonary contusion. Shock 2007;28:447-52. [Crossref] [PubMed]
69. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-103. [Crossref] [PubMed]
70. Sha Q, Truong-Tran AQ, Plitt JR, et al. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004;31:358-64. [Crossref] [PubMed]
71. Guillot L, Le Goffic R, Bloch S, et al. Involvement of toll-like receptor 3 within the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005;280:5571-80. [Crossref] [PubMed]
72. Juarez E, Nuñez C, Sada E, et al. Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res 2010;11:2. [Crossref] [PubMed]
73. Schreibelt G, Tel J, Sliepen KH, et al. Toll-like receptor expression and performance in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Most cancers Immunol Immunother 2010;59:1573-82. [Crossref] [PubMed]
74. Wong JJM, Tan HL, Foo CWT, et al. A excessive dimensionality method reveals immunopathogenic responses driving extreme pediatric acute respiratory misery syndrome. Nat Commun 2026;17:6466. [Crossref] [PubMed]
75. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors categorical completely different toll-like receptors and reply to completely different microbial antigens. J Exp Med 2001;194:863-9. [Crossref] [PubMed]
76. Hanten JA, Vasilakos JP, Riter CL, et al. Comparability of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 2008;9:39. [Crossref] [PubMed]
77. Kawai T, Akira S. The function of pattern-recognition receptors in innate immunity: replace on Toll-like receptors. Nat Immunol 2010;11:373-84. [Crossref] [PubMed]
78. Totura AL, Whitmore A, Agnihothram S, et al. Toll-Like Receptor 3 Signaling by way of TRIF Contributes to a Protecting Innate Immune Response to Extreme Acute Respiratory Syndrome Coronavirus An infection. mBio 2015;6:e00638-15. [Crossref] [PubMed]
79. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells by way of the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200. [Crossref] [PubMed]
80. Marchant EA, Kan B, Sharma AA, et al. Attenuated innate immune defenses in very untimely neonates through the neonatal interval. Pediatr Res 2015;78:492-7. [Crossref] [PubMed]
81. Le Goffic R, Pothlichet J, Vitour D, et al. Reducing Edge: Influenza A virus prompts TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol 2007;178:3368-72. [Crossref] [PubMed]
82. Abraham E. Neutrophils and acute lung harm. Crit Care Med 2003;31:S195-S199. [Crossref] [PubMed]
83. Ryu JH, Kim CH, Yoon JH. Innate immune responses of the airway epithelium. Mol Cells. 2010;30:173-83. [Crossref] [PubMed]
84. Le Goffic R, Balloy V, Lagranderie M, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2006;2:e53. [Crossref] [PubMed]
85. Chun CD, Liles WC, Frevert CW, et al. Mechanical air flow modulates Toll-like receptor-3-induced lung irritation by way of a MyD88-dependent, TLR4-independent pathway: a managed animal research. BMC Pulm Med 2010;10:57. [Crossref] [PubMed]
86. Miles MA, Jayawardena S, Liong S, et al. TLR7 deficiency enhances irritation within the URT however reduces LRT immunity following influenza A an infection. Sci Rep 2025;15:18918. [Crossref] [PubMed]
87. Huang H, Zhu J, Gu L, et al. TLR7 Mediates Acute Respiratory Misery Syndrome in Sepsis by Sensing Extracellular miR-146a. Am J Respir Cell Mol Biol 2022;67:375-88. [Crossref] [PubMed]
88. Miles MA, Liong S, Liong F, et al. TLR7 promotes power airway illness in RSV-infected mice. Entrance Immunol 2023;14:1240552. [Crossref] [PubMed]
89. Xirakia C, Koltsida O, Stavropoulos A, et al. Toll-like receptor 7-triggered immune response within the lung mediates acute and long-lasting suppression of experimental bronchial asthma. Am J Respir Crit Care Med 2010;181:1207-16. [Crossref] [PubMed]
90. Tang J, Solar M, Shi G, et al. Toll-Like Receptor 8 Agonist Strengthens the Protecting Efficacy of ESAT-6 Immunization to Mycobacterium tuberculosis An infection. Entrance Immunol 2017;8:1972. [Crossref] [PubMed]
91. Knuefermann P, Baumgarten G, Koch A, et al. CpG oligonucleotide prompts Toll-like receptor 9 and causes lung irritation in vivo. Respir Res 2007;8:72. [Crossref] [PubMed]
92. Suresh MV, Thomas B, Dolgachev VA, et al. Toll-Like Receptor-9 (TLR9) is Requisite for Acute Inflammatory Response and Damage Following Lung Contusion. Shock 2016;46:412-9. [Crossref] [PubMed]
93. Uhlig S, Kuebler WM. Difficulties in modelling ARDS (2017 Grover Convention Collection). Pulm Circ 2018;8:2045894018766737. [Crossref] [PubMed]
94. Kulkarni HS, Lee JS, Bastarache JA, et al. Replace on the Options and Measurements of Experimental Acute Lung Damage in Animals: An Official American Thoracic Society Workshop Report. Am J Respir Cell Mol Biol 2022;66:e1-e14. [Crossref] [PubMed]
95. Bastarache JA, Blackwell TS. Growth of animal fashions for the acute respiratory misery syndrome. Dis Mannequin Mech 2009;2:218-23. [Crossref] [PubMed]
96. Matute-Bello G, Frevert CW, Martin TR. Animal fashions of acute lung harm. Am J Physiol Lung Cell Mol Physiol 2008;295:L379-99. [Crossref] [PubMed]
97. Matute-Bello G, Downey G, Moore BB, et al. An official American Thoracic Society workshop report: options and measurements of experimental acute lung harm in animals. Am J Respir Cell Mol Biol 2011;44:725-38. [Crossref] [PubMed]
98. Zhai R, Bonda WLM, Matute-Bello G, et al. From preclinical to scientific fashions of acute respiratory misery syndrome. Signa Vitae 2022;18:3-14.
99. Parsons PE. Bridging the chasm between bench and bedside: translational analysis in acute lung harm. Am J Physiol Lung Cell Mol Physiol 2004;286:L1086-7. [Crossref] [PubMed]
100. Rittirsch D, Flierl MA, Ward PA. Dangerous molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776-87. [Crossref] [PubMed]
101. Bakopoulos A, Kapelouzou A, Tsilimigras DI, et al. Expression of Toll-like receptors (TLRs) within the lungs of an experimental sepsis mouse mannequin. PLoS One 2017;12:e0188050. [Crossref] [PubMed]
102. Alzahrani B, Gaballa MMS, Tantawy AA, et al. Blocking Toll-like receptor 9 attenuates bleomycin-induced pulmonary harm. J Pathol Transl Med 2022;56:81-91. [Crossref] [PubMed]
103. Tiba MH, McCracken BM, Leander DC, et al. A novel swine mannequin of the acute respiratory misery syndrome utilizing clinically related harm exposures. Physiol Rep 2021;9:e14871. [Crossref] [PubMed]
104. Kaslow SR, Reimer JA, Pinezich MR, et al. A clinically related mannequin of acute respiratory misery syndrome in human-size swine. Dis Mannequin Mech 2022;15:dmm049603. [Crossref] [PubMed]
105. Barbeta E, Arrieta M, Motos A, et al. A protracted-lasting porcine mannequin of ARDS brought on by pneumonia and ventilator-induced lung harm. Crit Care 2023;27:239. [Crossref] [PubMed]
106. Schittny JC. How excessive decision three-dimensional imaging adjustments our understanding of postnatal lung improvement. Histochem Cell Biol 2018;150:677-91. [Crossref] [PubMed]
107. Wang T, Wang L, Zhu X, et al. Correlation between TLR4 gene polymorphism and acute respiratory misery syndrome after esophageal most cancers surgical procedure. Am J Transl Res 2021;13:3337-43.
108. Ding Y, Feng Q, Chen J, et al. TLR4/NF-κB signaling pathway gene single nucleotide polymorphisms alter gene expression ranges and have an effect on ARDS incidence and prognosis outcomes. Medication (Baltimore) 2019;98:e16029. [Crossref] [PubMed]
109. Zacher C, Schönfelder Okay, Rohn H, et al. The only nucleotide polymorphism rs4986790 (c.896A>G) within the gene TLR4 as a protecting consider corona virus illness 2019 (COVID-19). Entrance Immunol 2024;15:1355193. [Crossref] [PubMed]
110. Lim HK, Huang SXL, Chen J, et al. Extreme influenza pneumonitis in kids with inherited TLR3 deficiency. J Exp Med 2019;216:2038-56. [Crossref] [PubMed]
111. Esposito S, Molteni CG, Giliani S, et al. Toll-like receptor 3 gene polymorphisms and severity of pandemic A/H1N1/2009 influenza in in any other case wholesome kids. Virol J 2012;9:270. [Crossref] [PubMed]
112. Wurfel MM, Gordon AC, Holden TD, et al. Toll-like receptor 1 polymorphisms have an effect on innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 2008;178:710-20. [Crossref] [PubMed]
113. Currie AJ, Curtis S, Strunk T, et al. Preterm infants have poor monocyte and lymphocyte cytokine responses to group B streptococcus. Infect Immun 2011;79:1588-96. [Crossref] [PubMed]
114. Lavoie PM, Huang Q, Jolette E, et al. Profound lack of interleukin (IL)-12/IL-23p40 in neonates born early in gestation is related to an elevated threat of sepsis. J Infect Dis 2010;202:1754-63. [Crossref] [PubMed]
115. Viemann D, Dubbel G, Schleifenbaum S, et al. Expression of toll-like receptors in neonatal sepsis. Pediatr Res 2005;58:654-9. [Crossref] [PubMed]
116. Burl S, Townend J, Njie-Jobe J, et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One 2011;6:e18185. [Crossref] [PubMed]
117. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Skilled Rev Clin Immunol 2014;10:1171-84. [Crossref] [PubMed]
118. Dowling DJ, Levy O. Ontogeny of youth immunity. Developments Immunol 2014;35:299-310. [Crossref] [PubMed]
119. Liao SL, Yeh KW, Lai SH, et al. Maturation of Toll-like receptor 1-4 responsiveness throughout youth. Early Hum Dev 2013;89:473-8. [Crossref] [PubMed]
120. Sadeghi Okay, Berger A, Langgartner M, et al. Immaturity of an infection management in preterm and time period newborns is related to impaired toll-like receptor signaling. J Infect Dis 2007;195:296-302. [Crossref] [PubMed]
121. Ozato Okay, Tsujimura H, Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression within the immune system. Biotechniques 2002;66-8, 70, 72 passim.
122. Clapp DW. Developmental regulation of the immune system. Semin Perinatol 2006;30:69-72. [Crossref] [PubMed]
123. Uebelhoer LS, Gwela A, Thiel B, et al. Toll-Like Receptor-Induced Immune Responses Throughout Early Childhood and Their Associations With Scientific Outcomes Following Acute Sickness Amongst Infants in Sub-Saharan Africa. Entrance Immunol 2021;12:748996. [Crossref] [PubMed]
124. van Haren SD, Dowling DJ, Foppen W, et al. Age-Particular Adjuvant Synergy: Twin TLR7/8 and Mincle Activation of Human New child Dendritic Cells Permits Th1 Polarization. J Immunol 2016;197:4413-24. [Crossref] [PubMed]
125. Wynn JL, Cvijanovich NZ, Allen GL, et al. The affect of developmental age on the early transcriptomic response of youngsters with septic shock. Mol Med 2011;17:1146-56. [Crossref] [PubMed]
126. Smith LS, Zimmerman JJ, Martin TR. Mechanisms of acute respiratory misery syndrome in kids and adults: a assessment and recommendations for future analysis. Pediatr Crit Care Med 2013;14:631-43. [Crossref] [PubMed]
127. Kneyber MC, Zhang H, Slutsky AS. Ventilator-induced lung harm. Similarity and variations between kids and adults. Am J Respir Crit Care Med 2014;190:258-65.
128. Hiruma T, Tsuyuzaki H, Uchida Okay, et al. IFN-β Improves Sepsis-related Alveolar Macrophage Dysfunction and Postseptic Acute Respiratory Misery Syndrome-related Mortality. Am J Respir Cell Mol Biol 2018;59:45-55. [Crossref] [PubMed]
129. Zhang C, Ji Y, Xue H, et al. Correlation of Toll-like Receptor Single Nucleotide Polymorphisms with Susceptibility to Infectious ARDS in Kids. Revista Argentina de Clínica Psicológica 2021;30:360-6.
130. Wong JJM, Tan HL, Zhou J, et al. Massive scale cytokine profiling uncovers elevated IL12-p70 and IL-17A in extreme pediatric acute respiratory misery syndrome. Sci Rep 2021;11:14158. [Crossref] [PubMed]
131. Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice from deadly influenza an infection. Nature 2013;497:498-502. [Crossref] [PubMed]
132. Shah D, Das P, Acharya S, et al. Small Immunomodulatory Molecules as Potential Therapeutics in Experimental Murine Fashions of Acute Lung Damage (ALI)/Acute Respiratory Misery Syndrome (ARDS). Int J Mol Sci 2021;22:2573. [Crossref] [PubMed]
133. Opal SM, Laterre PF, Francois B, et al. Impact of eritoran, an antagonist of MD2-TLR4, on mortality in sufferers with extreme sepsis: the ACCESS randomized trial. JAMA 2013;309:1154-62. [Crossref] [PubMed]
134. Bian WY, Chen YP, Xu B, et al. Pretreatment with Propofol Reduces Pulmonary Damage in a Pig Mannequin of Intestinal Ischemia-Reperfusion by way of Suppressing the Excessive-Mobility Group Field 1 Protein (HMGB1)/Toll-Like Receptor 4 (TLR4)/Protein Kinase R (PKR) Signaling Pathway. Med Sci Monit 2021;27:e930478. [Crossref] [PubMed]
135. Kawamoto T, Ii M, Kitazaki T, et al. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular area. Eur J Pharmacol 2008;584:40-8. [Crossref] [PubMed]
136. Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the remedy of extreme sepsis. Crit Care Med 2010;38:1685-94. [Crossref] [PubMed]
137. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial medicine and imidazoquinolines. J Immunol 2011;186:4794-804. [Crossref] [PubMed]
138. Lenert PS. Classification, mechanisms of motion, and therapeutic purposes of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm 2010;2010:986596. [Crossref] [PubMed]
139. Engeroff P, Belbézier A, Monsel A, et al. Anakinra reduces lung irritation in experimental acute lung harm. Immun Inflamm Dis 2022;10:123-9. [Crossref] [PubMed]
140. Declercq J, Van Damme KFA, De Leeuw E, et al. Impact of anti-interleukin medicine in sufferers with COVID-19 and indicators of cytokine launch syndrome (COV-AID): a factorial, randomised, managed trial. Lancet Respir Med 2021;9:1427-38. [Crossref] [PubMed]
141. Nasir N, Mahmood F, Habib Okay, et al. Tocilizumab for COVID-19 Acute Respiratory Misery Syndrome: Outcomes Evaluation Utilizing the WHO Ordinal Scale. Cureus 2020;12:e12290. [Crossref] [PubMed]
142. Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and security of baricitinib plus commonplace of take care of the remedy of critically in poor health hospitalised adults with COVID-19 on invasive mechanical air flow or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med 2022;10:327-36. [Crossref] [PubMed]
143. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and security of baricitinib for the remedy of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled section 3 trial. Lancet Respir Med 2021;9:1407-18. [Crossref] [PubMed]
144. Girkin JLN, Maltby S, Bartlett NW. Toll-like receptor-agonist-based therapies for respiratory viral illnesses: pondering exterior the cell. Eur Respir Rev 2022;31:210274. [Crossref] [PubMed]
145. Ghazaly MMH, Abu Faddan NH, Raafat DM, et al. Acute viral bronchiolitis as a explanation for pediatric acute respiratory misery syndrome. Eur J Pediatr 2021;180:1229-34. [Crossref] [PubMed]
146. Tocilizumab in sufferers admitted to hospital with COVID-19 (RECOVERY): a randomised, managed, open-label, platform trial. Lancet 2021;397:1637-45.
147. REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Sick Sufferers with Covid-19. N Engl J Med 2021;384:1491-502. [Crossref] [PubMed]
148. Salama C, Han J, Yau L, et al. Tocilizumab in Sufferers Hospitalized with Covid-19 Pneumonia. N Engl J Med 2021;384:20-30. [Crossref] [PubMed]
149. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in sufferers hospitalised with COVID-19 pneumonia: Efficacy, security, viral clearance, and antibody response from a randomised managed trial (COVACTA). EClinicalMedicine 2022;47:101409. [Crossref] [PubMed]
150. Meta-analysis A. JAMA 2021;326:499-518. WHO Speedy Proof Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, et al Affiliation Between Administration of IL-6 Antagonists and Mortality Amongst Sufferers Hospitalized for COVID-19:. [Crossref] [PubMed]
151. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early remedy of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma ranges: a double-blind, randomized managed section 3 trial. Nat Med 2021;27:1752-60. [Crossref] [PubMed]
152. Impact of anakinra versus common care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised managed trial. Lancet Respir Med 2021;9:295-304.
153. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in extreme sepsis: a section III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997;25:1115-24.
154. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is Related With Lowered Mortality in Sepsis Sufferers With Options of Macrophage Activation Syndrome: Reanalysis of a Prior Part III Trial. Crit Care Med 2016;44:275-81. [Crossref] [PubMed]
155. Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung harm: outcomes of the STRIVE research. Crit Care Med 2004;32:1695-702. [Crossref] [PubMed]
156. Baricitinib in sufferers admitted to hospital with COVID-19 (RECOVERY): a randomised, managed, open-label, platform trial and up to date meta-analysis. Lancet 2022;400:359-68.
157. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 2021;384:795-807. [Crossref] [PubMed]
158. Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med 2022;10:888-99. [Crossref] [PubMed]
159. Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in Sufferers Hospitalized with Covid-19 Pneumonia. N Engl J Med 2021;385:406-15. [Crossref] [PubMed]
160. McKinnon JE, Santiaguel J, Murta de Oliveira C, et al. Enpatoran in COVID-19 pneumonia: Security and efficacy outcomes from a section II randomized trial. Clin Transl Sci 2023;16:2640-53. [Crossref] [PubMed]
161. Wei Q, Lin J, Li Y. Albiflorin attenuates sepsis-induced acute lung harm (ALI) by way of the TLR-4/NF-κB pathway. Journal of Practical Meals 2023;107:105633.
162. Pan W, Xu X, Wang Y, et al. Interleukin-35 reduces irritation in acute lung harm via inhibiting TLR4/NF-κB signaling pathways. Exp Ther Med 2020;19:1695-700. [Crossref] [PubMed]

Cite this text as: Foo CWT, Tan HL, Leong JY, Yeo JG, Albani S, Wong JJM. A developmentally knowledgeable narrative assessment of Toll-like receptors in grownup and pediatric acute respiratory misery syndrome. Ann Transl Med 2026;14(4):54. doi: 10.21037/atm-2026-0138